Benjamin Burnett
Stock Analyst at Wells Fargo
(3.88)
# 619
Out of 5,134 analysts
87
Total ratings
59.09%
Success rate
8.51%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Benjamin Burnett
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AXSM Axsome Therapeutics | Maintains: Overweight | $157 → $193 | $183.30 | +5.29% | 3 | Jan 13, 2026 | |
| CNTA Centessa Pharmaceuticals | Maintains: Overweight | $30 → $35 | $24.98 | +40.11% | 3 | Nov 13, 2025 | |
| ALKS Alkermes | Maintains: Overweight | $42 → $37 | $32.90 | +12.46% | 3 | Nov 13, 2025 | |
| FATE Fate Therapeutics | Maintains: Hold | $5 → $3 | $1.34 | +123.88% | 3 | Mar 6, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Hold | $53 → $49 | $53.17 | -7.84% | 6 | Feb 13, 2025 | |
| ACLX Arcellx | Maintains: Buy | $83 → $122 | $70.13 | +73.98% | 5 | Oct 18, 2024 | |
| BEAM Beam Therapeutics | Maintains: Buy | $66 → $69 | $27.49 | +151.00% | 2 | Sep 11, 2024 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $63 → $68 | $30.76 | +121.07% | 7 | Sep 10, 2024 | |
| ALLO Allogene Therapeutics | Maintains: Hold | $4.4 → $4.6 | $2.16 | +112.96% | 5 | May 14, 2024 | |
| ATRA Atara Biotherapeutics | Maintains: Hold | $120 → $58 | $4.49 | +1,180.62% | 4 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $690 → $780 | $3.99 | +19,448.87% | 2 | Sep 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $29 → $27 | $12.59 | +114.46% | 3 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $43 | $29.06 | +47.97% | 1 | Feb 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $282 | $328.04 | -14.03% | 1 | Feb 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $65 → $45 | $20.18 | +122.99% | 1 | Dec 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $9 | $5.73 | +57.07% | 1 | Dec 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $217 → $234 | $150.52 | +55.46% | 1 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $48 | $41.66 | +15.22% | 3 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $8 | $5.54 | +44.40% | 1 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $23 | $16.52 | +39.23% | 1 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $73 → $93 | $69.17 | +34.45% | 1 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $414 → $423 | $482.42 | -12.32% | 1 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $64 | $100.61 | -36.39% | 5 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $94 | $65.57 | +43.36% | 7 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $5.21 | +91.94% | 3 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $2.62 | +854.20% | 11 | Sep 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $330 → $360 | $73.82 | +387.67% | 2 | Jun 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $16 | $0.37 | +4,224.32% | 1 | Jan 6, 2021 |
Axsome Therapeutics
Jan 13, 2026
Maintains: Overweight
Price Target: $157 → $193
Current: $183.30
Upside: +5.29%
Centessa Pharmaceuticals
Nov 13, 2025
Maintains: Overweight
Price Target: $30 → $35
Current: $24.98
Upside: +40.11%
Alkermes
Nov 13, 2025
Maintains: Overweight
Price Target: $42 → $37
Current: $32.90
Upside: +12.46%
Fate Therapeutics
Mar 6, 2025
Maintains: Hold
Price Target: $5 → $3
Current: $1.34
Upside: +123.88%
CRISPR Therapeutics AG
Feb 13, 2025
Maintains: Hold
Price Target: $53 → $49
Current: $53.17
Upside: -7.84%
Arcellx
Oct 18, 2024
Maintains: Buy
Price Target: $83 → $122
Current: $70.13
Upside: +73.98%
Beam Therapeutics
Sep 11, 2024
Maintains: Buy
Price Target: $66 → $69
Current: $27.49
Upside: +151.00%
IDEAYA Biosciences
Sep 10, 2024
Maintains: Buy
Price Target: $63 → $68
Current: $30.76
Upside: +121.07%
Allogene Therapeutics
May 14, 2024
Maintains: Hold
Price Target: $4.4 → $4.6
Current: $2.16
Upside: +112.96%
Atara Biotherapeutics
Apr 1, 2024
Maintains: Hold
Price Target: $120 → $58
Current: $4.49
Upside: +1,180.62%
Sep 10, 2021
Maintains: Buy
Price Target: $690 → $780
Current: $3.99
Upside: +19,448.87%
Feb 12, 2026
Maintains: Overweight
Price Target: $29 → $27
Current: $12.59
Upside: +114.46%
Feb 2, 2026
Initiates: Overweight
Price Target: $43
Current: $29.06
Upside: +47.97%
Feb 2, 2026
Initiates: Equal-Weight
Price Target: $282
Current: $328.04
Upside: -14.03%
Dec 30, 2025
Maintains: Overweight
Price Target: $65 → $45
Current: $20.18
Upside: +122.99%
Dec 18, 2025
Maintains: Overweight
Price Target: $7 → $9
Current: $5.73
Upside: +57.07%
Dec 16, 2025
Maintains: Overweight
Price Target: $217 → $234
Current: $150.52
Upside: +55.46%
Dec 11, 2025
Maintains: Overweight
Price Target: $44 → $48
Current: $41.66
Upside: +15.22%
Nov 11, 2025
Maintains: Overweight
Price Target: $10 → $8
Current: $5.54
Upside: +44.40%
Nov 11, 2025
Maintains: Overweight
Price Target: $26 → $23
Current: $16.52
Upside: +39.23%
Nov 5, 2025
Maintains: Overweight
Price Target: $73 → $93
Current: $69.17
Upside: +34.45%
Oct 30, 2025
Maintains: Equal-Weight
Price Target: $414 → $423
Current: $482.42
Upside: -12.32%
Apr 1, 2025
Maintains: Buy
Price Target: $78 → $64
Current: $100.61
Upside: -36.39%
Jan 24, 2025
Maintains: Buy
Price Target: $90 → $94
Current: $65.57
Upside: +43.36%
Jun 3, 2024
Maintains: Buy
Price Target: $7 → $10
Current: $5.21
Upside: +91.94%
Sep 15, 2023
Reiterates: Buy
Price Target: $25
Current: $2.62
Upside: +854.20%
Jun 28, 2021
Upgrades: Buy
Price Target: $330 → $360
Current: $73.82
Upside: +387.67%
Jan 6, 2021
Initiates: Hold
Price Target: $16
Current: $0.37
Upside: +4,224.32%